Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:ARTV 17 October 2025 - 16 December 2025

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics shares surged to around $6.30 on December 16 after trading between $4.08 and $7.25 in a session with volume near 48 million shares. CEO Fred Aslan disclosed selling 3,187 shares at $6.00 each on December 15 under a pre-arranged plan, according to an SEC Form 4. The company’s market cap stands near $155 million.
16 December 2025
Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics shares surged nearly 100% in after-hours trading Oct. 16 after the FDA granted Fast Track status to its AlloNK cell therapy for refractory rheumatoid arthritis. The stock jumped from a $2.77 close to as high as $6.33. Over 20 patients have received AlloNK in trials, with key safety and mechanistic data expected by mid-November. Artiva plans to begin a pivotal Phase 3 trial in 2026, pending results.
17 October 2025
·
Go toTop